Plus Therapeutics Executes 1-for-25 Reverse Stock Split to Avoid Nasdaq Delisting
Event summary
- Plus Therapeutics approved a 1-for-25 reverse stock split effective April 2, 2026.
- The move reduces outstanding shares from ~171.6M to ~6.9M to meet Nasdaq's $1 minimum bid price requirement.
- Trading will resume under the same ticker (PSTV) with a new CUSIP number (72941H806).
- Fractional shares will be paid out in cash, and equity awards/warrants will be adjusted proportionally.
The big picture
The reverse stock split is a defensive maneuver to retain Nasdaq listing, common among small-cap biotechs facing delisting risks. While it preserves market access, the structural change may signal broader challenges in achieving clinical milestones or securing financing. The move echoes broader industry trends where pre-revenue biotechs balance exchange compliance with R&D execution.
What we're watching
- Liquidity Impact
- How the reduced share count affects trading volume and institutional investor participation.
- Compliance Sustainability
- Whether Plus Therapeutics can maintain the $1 share price threshold post-split.
- Strategic Priorities
- The pace at which the company advances its pipeline amid capital structure adjustments.
Related topics